Publication:
COVID-19 pnömonisinde kortikosteroid kullanımı

Simple item page
dc.contributor.authorYıldız Gülhan, Pınar
dc.contributor.authorErçen Diken, Özlem
dc.contributor.authorÖzkaya, Şevket
dc.contributor.authorDeniz, Pelin Pınar
dc.contributor.authorYıldırım, Fatma
dc.contributor.authorŞimşek, Meltem
dc.contributor.authorYücel, Cihan
dc.contributor.authorBerik Safçi, Sinem
dc.contributor.authorCoşkun Çelik, Şakire Müge
dc.contributor.authorDirican, Adem
dc.contributor.authorSöğüt Akdağ, Devrim
dc.contributor.institutionDÜZCE ÜNİVERSİTESİ
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionBAHÇEŞEHİR ÜNİVERSİTESİ
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionSAĞLIK BİLİMLERİ ÜNİVERSİTESİ
dc.contributor.institutionSAĞLIK BİLİMLERİ ÜNİVERSİTESİ
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.date.accessioned2025-09-20T19:57:18Z
dc.date.issued2021
dc.date.submitted01.06.2022
dc.description.abstractGiriş: Koronavirüs hastalığı 2019 (COVID-19), henüz spesifik bir tedavi tanımlanmayan %1-2'lik bir ölüm oranına sahiptir. Akut respiratuvar distres sendromu (ARDS) veya septik şok olmayan seçilmiş COVID-19 hastaları için kortikosteroidler önerilse de, hasta alt\rgrupları, dozu ve süresi konusunda fikir birliği yoktur. Bu çalışmada kortikosteroid tedavisinin ARDS veya septik şok olmaksızın\rCOVID-19 pnömoni yönetimine katkısını hem akut hem de iyileşme ortamında incelemeyi amaçladık.\rMateryal ve Metod: Çalışma popülasyonu, iyileşme aşamasında kortikosteroid kullananlar (yeterli radyolojik veya klinik iyileşme\rgeliştirmeyenler) ve aktivasyon döneminde (ARDS dışı/septik şok durumu, klinik, laboratuvar veya radyolojik progresyon olarak ikiye\rayrıldı).\rBulgular: Yirmi altısı erkek ve yaş ortalaması 60,5 ± 16,5 yıl olan 47 hasta belirledik. On yedi hastanın (%36,2) iyileşme aşamasında,\rgeri kalanının (n= 30) aktivasyon döneminde kortikosteroid aldığı tespit edildi. Kortikosteroid tedavisinden sonra, artan tedavi öncesi\rD-dimer, ferritin, CRP seviyelerinde azalma ve tedavi öncesi lenfosit sayısında ve satürasyonda azalma olduğunu bulduk. Aktivasyon\rfazında ve iyileşme fazında sırasıyla hastaların %6,9 ve %17,6'sında tam semptomatik iyileşme tespit edildi. Aktivasyon fazında ve\riyileşme fazında sırasıyla hastaların %11,5 ve %35,3'ünde tam radyolojik iyileşme saptandı. Kortikosteroid tedavisine 4,2 ± 2,6 gün\rbaşlanıp aktivasyon grubunda ortalama 5,9 ± 2,8 gün devam edilirken, iyileşme grubunda 8,1 ± 11,3 gün başlandı ve 7,8 ± 3,8 gün\ruygulandı. Her iki grupta da metilprednizolon medyan 40 mg/gün dozunda verildi.\rSonuç: Kısa süreli düşük doz kortikosteroid tedavisi, ARDS ve septik olmayan şok olmayan aktivasyon döneminde ve tatmin edici\ryanıt alınamayan iyileşme döneminde COVID-19 pnömonisinin tedavisinde klinik, radyolojik ve laboratuvar sonuçları iyileştirebilir.\rDiğer randomize kontrollü çalışmalar kortikosteroidlerin etkinliğini göstermede faydalı olacaktır.
dc.identifier.doi10.5578/tt.20219811
dc.identifier.endpage226
dc.identifier.issn0494-1373
dc.identifier.issue2
dc.identifier.startpage217
dc.identifier.urihttps://hdl.handle.net/20.500.14719/4826
dc.identifier.volume69
dc.language.isoen
dc.relation.journalTüberküloz ve Toraks
dc.subjectSolunum Sistemi
dc.subjectEnfeksiyon Hastalıkları
dc.titleCOVID-19 pnömonisinde kortikosteroid kullanımı
dc.typeResearch Article
dcterms.references1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395(10229): 1054-62.,2. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020, 48(2): 155-63.,3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020, 323(13): 1239-42.,4. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020, 6(10): 1192-8.,5. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis 2020: ciaa478.,6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19 - Preliminary Report. N Engl J Med 2021, 384(8): 693-704.,7. Zeng F, Li L, Zeng J, Deng Y, Huang H, Chen B, et al. Can we predict the severity of coronavirus disease 2019 with a routine blood test? Pol Arch Intern Med 2020, 130(5): 400-6,8. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med 2020, 58(7): 1095-9.,9. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 2020, 30(8): 4381-9.,10. Wang Y, Jiang W, He Q, Wang C, Liu B, Zhou P, et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv 2020.,11. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 2020.,12. Sun F, Kou H, Wang S, Yun L, Houyu Z, Wenjing L, et al. Medication patterns and disease progression among 165 patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study. Ann Transl Med 2020, 9(4): 306.,13. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020, 180(7): 934-43.,14. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006, 3(9): e343.,15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395(10229): 1054-62.,16. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020, 71(15): 748-55.,17. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020, 20(10): 1135- 40.,18. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, GómezBarquero J, Abadía-Otero J, García-Ibarbia C. GLUCOCOVID investigators. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an openlabel randomized trial (GLUCOCOVID). Wien Klin Wochenschr 2021, 133(7-8): 303-11.,19. Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020, 43(3): 183-4.,20. Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D, Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med 2020, 46(6): 1124-6.,21. Rebuplic of Turkey Ministry of Health. COVID-19 Interim Guidance (T.C. Sağlık Bakanlığı COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi) 2020. Available from: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_ Rehberi.pdf?type=file,22. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 novel coronavirus (2019-NCoV). Radiology 2020, 295(1): 202-7.,23. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020, 20(4): 425-34.,24. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on Chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020:200370.,25. Roberton BJ, Hansell DM. Organizing pneumonia: a kaleidoscope of concepts and morphologies. Eur Radiol 2011, 21(11): 2244-54.,26. Liu H, Li J, Chen M, Su J. Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection: a case report. Medicine (Baltimore) 2019, 98(34): e16839.,27. He H, Wang H, Li X, Tang X, Sun B, Tong Z. Successful management of refractory respiratory failure caused by avian influenza H7N9 and secondary organizing pneumonia: a case report and literature review. BMC Infect Dis 2019, 19(1): 671.,28. Yoo JK, Kim TS, Hufford MM, Braciale TJ. Viral infection of the lung: host response and sequelae. J Allergy Clin Immunol 2013, 132(6): 1263-76.,29. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007, 117: 530-8.,30. Cano EJ, Fonseca Fuentes X, Corsini Campioli C, O’Horo JC, Abu Saleh O, Odeyemi Y et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest. 2021, 159(3): 1019-40.,31. Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al, PREDICO Study Group. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect 2021, 27(1): 105-11.,32. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021, 72(9): e373-e381.,33. Papamanoli A, Yoo J, Grewal P, Predun W, Hotelling J, Jacob R, et al. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. Eur J Clin Invest 2021, 51(2): e13458
dspace.entity.typePublication
local.indexed.atTRDizin

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Corticosteroid use in COVID-19 pneumonia.pdf
Size:
276.3 KB
Format:
Adobe Portable Document Format
Download

Collections

TR-Dizin İndeksli Yayınlar Koleksiyonu